课题基金 / 基金详情

项目摘要

项目成果

DAVID NEMAZEE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Autoreactive B cells play critical roles in many autoimmune diseases. Multiple immune tolerance checkpoints exist to remove autoreactive B cells or keep them under control. Defects in these checkpoints constitute the basis for the development of autoimmune diseases. Despite intensive study, our understanding of these checkpoints remains incomplete and fragmentary. MicroRNAs (miRNAs) are a new class of small non-coding RNAs that regulate a large diversity of biological processes. Hundreds of miRNAs are expressed in the immune system. While some miRNAs have been shown to play important roles in lymphocyte development and function, the roles of miRNAs in controlling immune tolerance remain poorly understood. We performed in vivo functional analysis of hundreds of miRNAs in the recently established IgMb-macroself mouse model and identified miR-148a as an important regulator of B cell central tolerance and autoimmunity (Nature Immunology 17:433-40, 2016). Further molecular analysis identified 119 target genes regulated by miR-148a in immature B cells. We examined 4 of these target genes and demonstrated that 3 of them, Gadd45a, Bim and Pten, regulate B cell central tolerance. In this proposal, we will 1) further investigate the cellular and molecular mechanisms underlying miR-148a regulation of immune tolerance and autoimmunity, focusing on its role in controlling various B cell tolerance checkpoints and plasma cell differentiation; 2) evaluate the possibility of treating systemic autoimmunity through miR-148a ablation and inhibition by genetic and chemical approaches, respectively, and 3) perform an in vitro functional screen of the other 115 miR-148a target genes to identify novel regulators of B cell tolerance. Our pilot screen has identified B4galt5 as a positive hit. As B4galt5 is a major enzyme in the glycolipid biosynthesis pathway, we speculate that this pathway plays important roles in immune tolerance. Therefore, we will elucidate the function and mechanism of B4galt5 and the glycolipid biosynthesis pathway in controlling B cell tolerance and autoimmunity.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Structural and mechanistic insights into disease-associated endolysosomal exonucleases PLD3 and PLD4.
对疾病相关内溶酶体核酸外切酶 PLD3 和 PLD4 的结构和机制的见解。
DOI: 10.1101/2023.11.20.567917
发表时间: 2023
期刊: bioRxiv : the preprint server for biology
影响因子: --
作者: [Yuan,Meng, Peng,Linghang, Huang,Deli, Gavin,Amanda, Luan,Fangkun, Tran,Jenny, Feng,Ziqi, Zhu,Xueyong, Matteson,Jeanne, Wilson,IanA, Nemazee,David]
通讯作者: Nemazee,David
DOI: 10.1126/sciadv.abb8087
发表时间: 2021-03
期刊: Science advances
影响因子: 13.6
作者: [Huang Z, Kang SG, Li Y, Zak J, Shaabani N, Deng K, Shepherd J, Bhargava R, Teijaro JR, Xiao C]
通讯作者: Xiao C
Role of PLD3 in nucleic acid recognition and brain function
  • 批准号:
    10525053
  • 项目类别:
  • 资助金额:
    $133.13万
  • 财政年份:
    2022
  • 负责人:
    DAVID NEMAZEE
  • 依托单位:
Role of PLD3 in nucleic acid recognition and brain function
  • 批准号:
    10388543
  • 项目类别:
  • 资助金额:
    $44.38万
  • 财政年份:
    2021
  • 负责人:
    DAVID NEMAZEE
  • 依托单位:
Immune Tolerance in Non-Clonal Immune Systems
  • 批准号:
    9546043
  • 项目类别:
  • 资助金额:
    $53.47万
  • 财政年份:
    2019
  • 负责人:
    DAVID NEMAZEE
  • 依托单位:
Knock-in mice expressing germline-reverted broadly neutralizing HIV antibodies
  • 批准号:
    10190786
  • 项目类别:
  • 资助金额:
    $67.91万
  • 财政年份:
    2019
  • 负责人:
    DAVID NEMAZEE
  • 依托单位:
海外基金